In many countries, including the United States, ibogaine is classified as a Schedule I controlled substance, making medical use and research highly restricted. The DEA controlled-substances schedule is the relevant federal reference when considering U.S. legal status.
Clinical trials typically move through phase I trials, phase II trials, and phase III trials to assess safety, dosage, and efficacy under regulatory standards. An investigational new drug pathway can allow controlled research before FDA approval; it is not evidence that a treatment is approved or available on demand.
Outside the United States, global ibogaine therapy is presented under varying regulatory frameworks, including commercial options in Mexico, Canada, and New Zealand. The overview of international ibogaine detox clinics can help distinguish travel-based treatment from formal clinical research.
Ethical considerations include informed consent, participant safety, honest discussion of adverse events, and protection against pressure. A compassionate use or special access route, where it exists, is jurisdiction-specific and still requires strict medical supervision.